CLOV vs PGNY

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Nov 09, 2026

CLOV

33.4
AI Score
VS
PGNY Wins

PGNY

39.2
AI Score

Investment Advisor Scores

CLOV

33score
Recommendation
AVOID NEW MONEY

PGNY

39score
Recommendation
EXTENDED

AI Analyst Insights

Detailed Metrics Comparison

Metric CLOV PGNY Winner
Forward P/E 37.7358 13.3511 PGNY
PEG Ratio 0 0 Tie
Revenue Growth 55.6% 5.3% CLOV
Earnings Growth 0.0% 78.9% PGNY
Tradestie Score 33.4/100 39.2/100 PGNY
Profit Margin -0.7% 6.0% PGNY
Beta 1.00 1.00 Tie
AI Recommendation AVOID NEW MONEY EXTENDED PGNY

Relative Price Performance (Last 90 Days)

CLOV 1M: +3.3% · 3M: +10.7% PGNY 1M: +33.3% · 3M: +41.0%

Current Technical Phase

CLOV

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (2.8% over 20 days), RSI 60

RSI (14): 59.7 · Price: $4.97

PGNY

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (5.6% over 20 days), RSI 83

RSI (14): 82.8 · Price: $36.50

Fundamentals Snapshot

Metric CLOV PGNY
Market Cap — —
Forward P/E 27.6 15.3
Trailing P/E 493.0 33.4
Revenue (TTM) — —
Revenue Growth 0.5% 0.1%
Gross Margin 0.2% 0.2%
Operating Margin 0.0% 0.1%
EPS 0.01 1.09
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, PGNY is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.